623562-63-0

Usage

Uses

Used in Pharmaceutical Synthesis:
[3-(4-nitro-phenoxy)-propyl]-carbamic acid tert-butyl ester is used as an intermediate in the pharmaceutical industry for the synthesis of various drugs. Its unique structure allows for the creation of a wide range of medicinal compounds with different therapeutic properties.
Used in Agrochemical Production:
In the agrochemical industry, [3-(4-nitro-phenoxy)-propyl]-carbamic acid tert-butyl ester is used as a building block for the development of pesticides and other crop protection agents. Its incorporation into these products can enhance their effectiveness in protecting crops from pests and diseases.
Used in Dye Manufacturing:
The 4-nitro-phenoxy group present in [3-(4-nitro-phenoxy)-propyl]-carbamic acid tert-butyl ester makes it a valuable component in the production of dyes. [3-(4-nitro-phenoxy)-propyl]-carbamic acid tert-butyl ester is used as a key ingredient in the dye industry to create a variety of colors for different applications, such as textiles, plastics, and printing inks.
Used in Research and Development:
Due to its versatile structure and potential applications, [3-(4-nitro-phenoxy)-propyl]-carbamic acid tert-butyl ester is also utilized in research and development laboratories. Scientists and researchers use [3-(4-nitro-phenoxy)-propyl]-carbamic acid tert-butyl ester to explore new chemical reactions, develop novel compounds, and study its properties for potential applications in various industries.

Upstream product

• 100-02-7 4-nitro-phenol 
• 58885-58-8 N-tert-butoxycarbonyl-3-aminopropanol 
• 350-46-9 4-Fluoronitrobenzene 
• 83948-53-2 3-bromopropylamine tert-butylcarbamate 
• 118119-47-4 di-tert-butyl dicarbonate 
• 100841-04-1 3-(4-nitrophenoxy)propan-1-amine 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 627463-31-4 ethyl-[3-(4-nitrophenoxy)propyl]carbamic acid tert-butyl ester 
• 22404-14-4 C₁₁H₁₄N₂O₄ 
• 1448718-83-9 (S)-N-[4-(3-tert-butoxycarbonylamino-propoxy)-phenyl]-3-(9H-fluoren-9-ylmethoxycarbonylamino )-succinamic acid tert-butyl ester 
• 1448718-84-0 (S)-3-amino-N-[4-(3-tert-butoxycarbonylamino-propoxy)-phenyl]-succinamic acid tert-butyl ester 
• 1448718-87-3 (S)-N-[4-(3-amino-propoxy)-phenyl]-3-(2-(3-(guanidino)-benzoylamino)-acetylamino)-succinamic acid trifluoroacetate 
• 1448718-88-4 (S)-N-[4-[3-[[3-[2-[2-[2-[2-[2-[2-[2-[2-[3-(2,5-dioxo-2,5-dihydro-pyrrol-1-yl)-propionylamino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]-1-oxopropyl]amino]propoxy]-phenyl]-3-[2-[3-[guanidino]-benzoylamino]-acetylamino]-succinamic acid 
• 100841-04-1 3-(4-nitrophenoxy)propan-1-amine 
• 66971-02-6 3-(4-nitrophenoxy)-1-propanol 
• 623562-59-4 C-{[4-[3-[N-(tert-butoxycarbonyl)amino]propan-1-yloxy]phenyl]amino}-N-[N-{(9S,12S)-7,10-dioxo-9-isopropyl-2-oxa-8,11-diazabicyclo[12.2.2]octadeca-14,16,17-trien-12-ylcarbonyl}glycyl]-(S)-isoleucine benzyl ester 

Relevant academic research and scientific papers

Functionalized azobenzene platinum(II) complexes as putative anticancer compounds

The synthesis and characterization of four platinum(II) complexes using azobenzenes conveniently functionalized as ligands has been carried out. The characteristic photochemical behavior of the complexes due to the presence of azobenzene-type ligands and the role of the ligands in the activation of the complexes has been studied. Their promising cytotoxicity observed in HeLa cells prompted us to study the mechanism of action of these complexes as cytostatic agents. The interaction of the compounds with DNA, studied by circular dichroism, revealed a differential activity of the Pt(II) complexes upon irradiation. The intercalation abilities of the complexes as well as their reactivity with common proteins present in the blood stream allows to confirm some of the compounds obtained as good anticancer candidates.

HETEROAROMATIC MACROCYCLIC DERIVATIVES AS PROTEIN KINASE INHIBITORS

The present invention relates to a 2,7-substituted cyano[3,2-d]pyrimidine cyclic compound having protein kinase inhibitory activity, a pharmaceutically acceptable salt thereof, and a pharmaceutical composition for preventing, alleviating, or treating a disease caused by abnormal cell growth, which includes the compound as an active ingredient. The novel 2,7-substituted cyano[3,2-d]pyrimidine cyclic compound of the present invention exhibits an excellent effect of inhibiting various protein kinases involved in the signal transduction of growth factors, and thus is effective as an agent for preventing, alleviating, or treating an abnormal cell growth disease caused by these protein kinases.

heteroaromatic macrocyclic derivatives as protein kinase inhibitors

The present invention relates to: a 2,7-substituted cyano[3,2-d]pyrimidine cyclized compound having protein kinase inhibitory activity; a pharmaceutically acceptable salt thereof; and a pharmaceutical composition for preventing, alleviating or treating diseases caused by abnormal cell growth which contains the compound as an active component. A novel 2,7-substituted cyano[3,2-d]pyrimidine cyclized compound of the present invention exhibits excellent inhibitory effects on various protein kinases involved in the growth factor signal transduction, thereby being useful as an agent for preventing, alleviating or treating abnormal cell growth diseases caused by these protein kinases.COPYRIGHT KIPO 2020

Using N-nitrosodichloroacetamides to conveniently convert linear primary amines into alcohols

The reported rearrangement of N-nitrosodichloroacetamides provides a practicalmethod for converting primary amines into primary alcohols. The reaction sequence is operationally simple, requires only a single purification, and is compatible with a number of common functional groups. Mechanistic studies of the nitrosylation and rearrangement reactions illustrate the increased utility of dichloroacetamides compared to various other amides for this transformation.

MACROCYCLES AS KINASE INHIBITORS

Compounds of the formula I in which X, Y, Q1, M, Q2 and B have the meanings indicated in Claim 1, are inhibitors of GCN2, and can be employed, inter alia, for the treatment of cancer.

INTEGRIN ANTAGONIST CONJUGATES FOR TARGETED DELIVERY TO CELLS EXPRESSING ALPHA-V-BETA-3

The invention relates to compounds of formula (I): wherein R1, R2, and n are defined in the detailed description and claims. In particular, the present invention relates to the compounds of formula (I) for use in the manufacture and delivery of conjugated moieties such as small molecules, peptides, nucleic acids, fluorescent moieties, and polymers which are linked to alpha-V-beta-3 integrin antagonists to target cells expressing alpha-V-beta-3.

CHITOSAN COVALENTLY LINKED WITH SMALL MOLECULE INTEGRIN ANTAGONIST FOR TARGETED DELIVERY

The invention relates to the chitosan polymer derivatives of formula I: and pharmaceutically acceptable salts and esters thereof, wherein Y, X1, X4, R1, R2, and n are defined in the detailed description and claims. The chitosan polymer derivatives of formula I bind to or associate with alpha-4-beta-1 (α4β1) and alpha-V-beta-3 (αVβ3) integrin dimers and can be used in delivery formulations to deliver drugs, nucleic acids, or other therapeutic compounds to tissues or cells expressing such integrins.

HETEROARYL COMPOUNDS AND USES THEREOF

The present invention provides inhibitors of protein kinases of formula I-a and I-b, pharmaceutically acceptable compositions thereof, and methods of using the same.

DIAMINOTHIAZOLES

The present invention is directed to novel diaminothiazoles of formula These compounds inhibit cyclin-dependent kinase 4 (Cdk4) and are selective against Cdk2 and Cdk1. These compounds and their pharmaceutically acceptable salts and esters have antiproliferative activity and are useful in the treatment or control of cancer, in particular solid tumors. This invention is also directed to pharmaceutical compositions containing such compounds and to methods of treating or controlling cancer, most particularly the treatment 6r control of breast, lung and colon and prostate tumors.